Skip to main content
Clinical Trials/NCT01921361
NCT01921361
Completed
Phase 4

The Effects of Dexmedetomidine on Peroperative Shivering Incidence Under Spinal Anesthesia

TC Erciyes University1 site in 1 country120 target enrollmentJanuary 2011

Overview

Phase
Phase 4
Intervention
Levobupivacaine
Conditions
Perioperative/Postoperative Complications
Sponsor
TC Erciyes University
Enrollment
120
Locations
1
Primary Endpoint
shivering score
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study to compare the efficacy of intravenous or intrathecal dexmedetomidine on the incidence of shivering on patients who scheduled spinal anesthesia for elective surgery.

Detailed Description

The design of the study includes three study groups done in random order. The groups are as follows: 1) Control group received 15 mg levobupivacaine intrathecally and intravenous 0.9% sodium chloride; 2) Intravenous group received 15 mg levobupivacaine intrathecally and intravenous dexmedetomidine (1mcg/kg/10min, 0.5mcg/kg/h infusion) ; 3) Intrathecal group received 15 mg levobupivacaine + 3 mcg dexmedetomidine intrathecally and intravenous 0.9% sodium chloride. Throughout the study period,shivering scores, tympanic temperature were recorded, heart rate were measured continuously using an electrocardiogram; blood pressure was determined oscillometrically at 5 min intervals at the ankle. In case heart rate decreased by more than 30% of the baseline atropin received and blood pressure decreased 30% of the baseline effedrin received. Side effects (bradycardia, hypotension, hypothermia, nausea and vomiting etc ) were recorded peroperatively in the operating room and postanesthetic care unit.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
January 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

RESUL ALTUNTAS

MD

TC Erciyes University

Eligibility Criteria

Inclusion Criteria

  • 18-65 y/o patients
  • American Society of Anesthesiologists' physical status class I-II
  • Scheduled for the spinal anesthesia

Exclusion Criteria

  • Patients who have the body temperature over 37.3 celsius degree
  • Pregnants
  • Known allergies to the study drugs
  • Contraindication to spinal anesthesia

Arms & Interventions

Intravenous

Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)

Intervention: Levobupivacaine

Intravenous

Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)

Intervention: Dexmedetomidine

Intravenous

Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)

Intervention: sodium chloride

Intrathecal

Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)

Intervention: Levobupivacaine

Intrathecal

Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)

Intervention: Dexmedetomidine

Intrathecal

Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)

Intervention: sodium chloride

Control

Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).

Intervention: Levobupivacaine

Control

Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).

Intervention: sodium chloride

Outcomes

Primary Outcomes

shivering score

Time Frame: 1 day (From start of anaesthesia till discharge from the recovery room )

Secondary Outcomes

  • core temperature(1 day (From start of anaesthesia till discharge from the recovery room ))
  • blood pressure(1 day (From start of anaesthesia till discharge from the recovery room ))
  • heart rate(1 day (From start of anaesthesia till discharge from the recovery room ))

Study Sites (1)

Loading locations...

Similar Trials